The European BRCA patent oppositions and appeals: coloring inside the lines.

Abstract

volume 31 NumBeR 8 AuGuST 2013 nature biotechnology or not the BRCA1 gene had been effectively isolated at the priority date, no real discussion about the patentability of the human genes (as occurred in the US), took place before the EPO. Hence, challenges to claims on genes and diagnostic methods based on a link between a genetic defect and a disease as… (More)
DOI: 10.1038/nbt.2644

2 Figures and Tables

Topics

  • Presentations referencing similar topics